Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio
SAN DIEGO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Resmed ( NYSE: RMD, ASX: RMD ) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, ...
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio - ResMed ( NYSE:RMD )
Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea
NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.
Why ResMed ( RMD ) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why ResMed ( RMD ) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's How Much You'd Have If You Invested $1000 in ResMed a Decade Ago
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
ResMed RMD Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, July 31, 2025 at 8:30 p.m. ETChief Executive Officer - Mick FarrellContinue reading ...
ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings - ResMed ( NYSE:RMD )
Resmed Inc RMD reported better-than-expected earnings for the second quarter on Thursday. The company posted quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.46 per share. The company reported quarterly sales of $1.348 billion which beat the analyst consensus ...
Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday - Apple ( NASDAQ:AAPL ) , Amazon.com ( NASDAQ:AMZN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Raymond James raised KLA Corporation KLAC price target from $850 to $950.
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.
ResMed ( RMD ) Surpasses Q4 Earnings and Revenue Estimates
ResMed (RMD) delivered earnings and revenue surprises of +3.66% and +1.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Earnings Preview: Evolus, Inc. ( EOLS ) Q2 Earnings Expected to Decline
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will ResMed ( RMD ) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Labcorp Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
LH tops Q2 estimates with double-digit EPS growth, margin gains and a raised 2025 outlook, lifting shares pre-market.
ResMed ( RMD ) Reports Next Week: Wall Street Expects Earnings Growth
ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
If You Invested $1000 in ResMed a Decade Ago, This is How Much It'd Be Worth Now
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up
BSX beats Q2 estimates, raises full-year outlook as Cardiovascular sales surge and global revenues climb 22.8%.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ResMed Inc. ( RMD ) Hit a 52 Week High, Can the Run Continue?
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises
DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.
Respiratory Care Devices Market is expected to generate a revenue of USD 40.31 Billion by 2031, Globally, at 5.89% CAGR: Verified Market Research®
Lewes, Delaware, July 21, 2025 ( GLOBE NEWSWIRE ) -- The Global Respiratory Care Devices Market Size is projected to grow at a CAGR of 5.89% from 2024 to 2031, according to a new report published by Verified Market Research®.
Sleep Apnea Devices Market is expected to generate a revenue of USD 14.59 Billion by 2031, Globally, at 10.42 % CAGR: Verified Market Research®
Lewes, Delaware, July 21, 2025 ( GLOBE NEWSWIRE ) -- The Global Sleep Apnea Devices Market Size is projected to grow at a CAGR of 10.42% from 2024 to 2031, according to a new report published by Verified Market Research®.
Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data
With retail sales rebounding and Wall Street gaining, low-leverage stocks like NVS, RMD, WAB, ESLT and INGR offer scope for upside.
Is Akebia Therapeutics ( AKBA ) Stock Outpacing Its Medical Peers This Year?
Here is how Akebia Therapeutics (AKBA) and ResMed (RMD) have performed compared to their sector so far this year.
Motley Fool Co-Founder David Gardner Reviews Stock Picks
We're approaching the 10-year anniversary of the first of Rule Breaker Investing's 30 five-stock samplers, picked from 2015 to 2021. In this special episode, Motley Fool co-founder David Gardner reflects on the updated results, sharing 10 fresh lessons from both the wins and the whiffs.
All You Need to Know About ResMed ( RMD ) Rating Upgrade to Buy
ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Scoop Up These 4 GARP Stocks to Receive Handsome Returns
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. SFM, ADBE, GE and RMD are some such stocks.
Looking Back on a Motley Fool Career
In this podcast, Motley Fool producer Rick Engdahl comes to the other side of the glass to reflect on what he's learned from 10 years of Rule Breaker Investing and a career at The Motley Fool.To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.
ResMed: A Mixed Bag for Investors Amid Rising Competition
Explore the exciting world of ResMed ( NYSE: RMD ) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of May 7, 2025.
Phibro ( PAHC ) Up 7.4% Since Last Earnings Report: Can It Continue?
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed ( RMD ) Up 4% Since Last Earnings Report: Can It Continue?
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
You may be surprised at how much wealth you can build by buying strong growth stocks and holding them over the long term. Investing in solid, growing businesses is one of the best ways you can earn the money needed to prepare yourself for a comfortable retirement.
Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 - ResMed ( NYSE:RMD )
SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 ( GLOBE NEWSWIRE ) -- Resmed RMDRMD ) , the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to ...
Resmed Acquires VirtuOx
Acquisition supports Resmed's growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers Acquisition supports Resmed's growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers ...
Resmed Acquires VirtuOx - ResMed ( NYSE:RMD )
SAN DIEGO, May 01, 2025 ( GLOBE NEWSWIRE ) -- Resmed RMDRMD ) , the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility ( IDTF ) for sleep, respiratory, and ...
MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up
Merit Medical benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter of 2025.
Buy These 5 Low-Leverage Stocks to Counter Market Volatility
The crux of safe investment lies in choosing a company that is not burdened with debt. You can buy BILI, KINS, ENGIY, ASML and RMD.
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast - ResMed ( NYSE:RMD )
Q3 sales rose 8% to $1.29 billion; adjusted EPS reached $2.37, beating expectations. Adjusted operating income jumped 13% to $444.6 million, net income up 11% to $348.5 million. Today's manic market swings are creating the perfect setup for Matt's next volatility trade.
Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday - Freshworks ( NASDAQ:FRSH ) , AMC Entertainment Hldgs ( NYSE:AMC )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS raised General Dynamics Corporation GD price target from $268 to $279.
Texas Instruments Posts Better-Than-Expected Results, Joins Community Health Systems, Hasbro, ServiceNow, ResMed And Other Big Stocks Moving Higher On Thursday - Ardagh Metal Packaging ( NYSE:AMBP ) , Allegion ( NYSE:ALLE )
U.S. stocks were higher, with the Nasdaq Composite gaining around 300 points on Thursday. Shares of Texas Instruments Incorporated TXN rose sharply during Thursday's session after the company reported first-quarter financial results and beat its EPS and sales estimates.
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market
RMD's stellar third-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
ResMed ( RMD ) Q3 Earnings and Revenues Surpass Estimates
ResMed (RMD) delivered earnings and revenue surprises of 0.42% and 0.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Resmed Names Salli Schwartz as Chief Investor Relations Officer
Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community ...
Resmed Names Salli Schwartz as Chief Investor Relations Officer - ResMed ( NYSE:RMD )
SAN DIEGO, April 21, 2025 ( GLOBE NEWSWIRE ) -- Resmed RMDRMD, ASX: RMD ) , the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025.
Earnings Preview: InMode ( INMD ) Q1 Earnings Expected to Decline
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Analyst Projections for Key Metrics Reveal About ResMed ( RMD ) Q3 Earnings
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
ResMed ( RMD ) Reports Next Week: Wall Street Expects Earnings Growth
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
